We believe Divi’s Labs Ltd. (DIVISLAB) has strong growth engines ahead to augment its growth and profitability over FY23-FY26E. During FY22-FY24E, it has been validating existing generic contrast media APIs and Sartan products with new set of potential customers as well as novel MRI API with innovator pharma company.